Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Apellis Pharmaceuticals, Inc. < Previous 1 2 3 Next > Apellis Pharmaceuticals to Present at Upcoming Investor Conferences February 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results February 20, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application January 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues January 08, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference December 28, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union December 14, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting December 11, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) November 04, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results November 01, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results October 25, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA) October 20, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week October 17, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023 October 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration October 02, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023 September 25, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at Upcoming Investor Conferences September 05, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at Upcoming Investor Conferences August 30, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success August 29, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection) August 22, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 04, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results July 31, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA) July 30, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
